论文部分内容阅读
本文报告了呼吸道合胞病毒(RSV)感染Vero细胞后经亲和层析提取的PFP-1疫苗在RSV血清阳性幼儿中的安全性和免疫原性。同时,作者认为蛋白印迹法(WB)对区别由PFP疫苗和RSV感染诱导的抗体滴度增高是一种有用的手段。 作者选择47名18～36月龄RSV血清阳性的健康幼儿,随机分为三组,比例为3:3:4,第1组接种含50μg蛋白的PFP-1疫苗,第2组接种含20μg蛋白的PFP-1疫苗,第3组接种三价流感病毒灭活(TIV)疫苗作为对照。分别于接种前、接种后4周及RSV流行季节末静脉采血,检测抗RSV抗体。根据注射部位
This article reports the safety and immunogenicity of the PFP-1 vaccine extracted by affinity chromatography after respiratory syncytial virus (RSV) infection in Vero cells in RSV seropositive infants. In the meantime, the authors consider Western blotting (WB) to be a useful tool for distinguishing between antibody titers induced by PFP and RSV infections. Forty-seven healthy children with RSV seropositivity at 18-36 months of age were randomly assigned to one of three groups with a ratio of 3: 3: 4, group 1 received a PFP-1 vaccine containing 50 μg of protein, and group 2 received 20 μg of protein PFP-1 vaccine and Group 3 vaccinated with trivalent influenza virus inactivated (TIV) vaccine as controls. Anti-RSV antibodies were detected before the inoculation, 4 weeks after inoculation and in the seasonal RSV epidemic seasons. According to the injection site